Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University Hospital Leipzig, Leipzig, Germany.
Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany.
Clin Gastroenterol Hepatol. 2018 May;16(5):730-737. doi: 10.1016/j.cgh.2017.09.017. Epub 2017 Sep 14.
BACKGROUND & AIMS: Organ allocation for liver transplantation is based on prognosis, using the model for end-stage liver disease (MELD) or MELD including serum sodium (MELD-Na) score. These scores do not consider systemic inflammation and septic complications. Blood level of C-reactive protein (CRP), in addition to the MELD score, associates with mortality in patients with end-stage liver disease, whereas levels of interleukin 6 (IL6) have not been systematically studied.
We performed a retrospective observational cohort study of 474 patients with end-stage liver disease (63.5% male; median age, 56.9 years), evaluated for liver transplantation in Germany, with at least 1 year of follow up. Data were collected on blood levels of CRP, IL6, and white blood cell count (WBC). Findings were analyzed in relation to mortality and compared with patients' MELD scores and MELD-Na scores. For survival analysis, the cohort was divided into quartiles of IL6, CRP, and WBC levels, as well as MELD scores. Log-rank test and the Cox proportional hazards regression model were used to compare the groups, and area under the receiver operating characteristic (AUROC) values were calculated.
Blood levels of IL6 and MELD scores associated with mortality: none of the patients with levels of IL6 below the first quartile (below 5.3 pg/mL) died within 1 year. In contrast, 67.7% of the patients in the highest quartile of IL6 level (37.0 pg/mL or more) died within 1 year. MELD score also correlated with mortality: among patients with MELD scores below 8.7, 0.9% died within 1 year, whereas in patients with MELD scores of 18.0 or more, 67.4% died within 1 year. The predictive value of level of IL6 (AUROC, 0.940) was higher than level of CRP (AUROC, 0.866) (P = .009) or WBC (AUROC, 0.773) (P < .001) for 90-day mortality. MELD scores associated with 90-day mortality (AUROC, 0.933) (P = .756) as did MELD-Na score (AUROC, 0.946) (P = .771). Level of IL6 associated with 1-year mortality (AUROC, 0.916) to a greater extent than liver synthesis or detoxification markers international normalized ratio (AUROC, 0.839) (P = .007) or bilirubin (AUROC 0.846) (P = .007). Level of IL6 was an independent, significant risk factor for mortality after adjustment for MELD score, MELD-Na score, level of CRP, or WBC.
In a retrospective analysis, we found high blood levels of IL6 to associate with 90-day and 1-year mortality in patients with end-stage liver disease; its predictive value was comparable to that of MELD or MELD-Na score, and was higher than that of level of CRP or WBC. Further studies should be performed to confirm the results in different cohorts.
肝移植的器官分配基于预后,使用终末期肝病模型(MELD)或包含血清钠的 MELD 评分(MELD-Na)。这些评分并未考虑全身炎症和脓毒症并发症。除了 MELD 评分外,C 反应蛋白(CRP)的血液水平与终末期肝病患者的死亡率相关,而白细胞介素 6(IL6)的水平尚未得到系统研究。
我们对德国接受肝移植评估的 474 名终末期肝病患者(63.5%为男性;中位年龄为 56.9 岁)进行了回顾性观察队列研究,随访时间至少为 1 年。收集了 CRP、IL6 和白细胞计数(WBC)的血液水平数据。分析结果与死亡率相关,并与患者的 MELD 评分和 MELD-Na 评分进行比较。为了进行生存分析,将队列按 IL6、CRP 和 WBC 水平以及 MELD 评分的四分位数进行分组。使用对数秩检验和 Cox 比例风险回归模型比较各组,并计算接受者操作特征(ROC)曲线下面积(AUROC)值。
IL6 血液水平和 MELD 评分与死亡率相关:在 1 年内没有任何 IL6 水平处于第一四分位数(低于 5.3pg/ml)的患者死亡。相比之下,IL6 水平最高四分位数(37.0pg/ml 或更高)的患者中有 67.7%在 1 年内死亡。MELD 评分也与死亡率相关:MELD 评分低于 8.7 的患者中,有 0.9%在 1 年内死亡,而 MELD 评分为 18.0 或更高的患者中,有 67.4%在 1 年内死亡。IL6 水平(AUROC,0.940)的预测价值高于 CRP 水平(AUROC,0.866)(P=0.009)或 WBC 水平(AUROC,0.773)(P<0.001),可用于预测 90 天死亡率。MELD 评分(AUROC,0.933)(P=0.756)和 MELD-Na 评分(AUROC,0.946)(P=0.771)与 90 天死亡率相关。IL6 水平与 1 年死亡率相关(AUROC,0.916)的程度大于肝合成或解毒标志物国际标准化比值(AUROC,0.839)(P=0.007)或胆红素(AUROC 0.846)(P=0.007)。在调整 MELD 评分、MELD-Na 评分、CRP 水平或 WBC 水平后,IL6 水平是死亡率的独立显著危险因素。
在回顾性分析中,我们发现终末期肝病患者的血液中 IL6 水平较高与 90 天和 1 年死亡率相关;其预测价值与 MELD 或 MELD-Na 评分相当,且高于 CRP 或 WBC 水平。应在不同的队列中开展进一步的研究以确认这些结果。